Ceylon cinnamon does not affect postprandial plasma glucose or insulin in subjects with impaired glucose tolerance

Jennie Wickenberg1,2, Sandra Lindstedt3, Kerstin Berntorp4, Jan Nilsson1,2 and Joanna Hlebowicz1,2,5*

1Center for Emergency, Skåne University Hospital, Lund University, Malmö, Sweden
2Department of Clinical Science, Lund University, Malmö, Sweden
3Department of Cardio-thoracic Surgery, Skåne University Hospital, Lund University, Lund, Sweden
4Department of Endocrinology, Skåne University Hospital, Lund University, Malmö, Sweden
5Department of Cardiology, Skåne University Hospital, Entrance 35, SE-205 02 Malmö, Sweden

(Submitted 23 March 2011 – Final revision received 16 August 2011 – Accepted 16 August 2011 – First published online 20 September 2011)

Abstract
Previous studies on healthy subjects have shown that the intake of 6 g Cinnamomum cassia reduces postprandial glucose and that the intake of 3 g C. cassia reduces insulin response, without affecting postprandial glucose concentrations. Coumarin, which may damage the liver, is present in C. cassia, but not in Cinnamomum zeylanicum. The aim of the present study was to study the effect of C. zeylanicum on postprandial concentrations of plasma glucose, insulin, glycaemic index (GI) and insulinaemic index (GII) in subjects with impaired glucose tolerance (IGT). A total of ten subjects with IGT were assessed in a crossover trial. A standard 75 g oral glucose tolerance test (OGTT) was administered together with placebo or C. zeylanicum capsules. Finger-prick capillary blood samples were taken for glucose measurements and venous blood for insulin measurements, before and at 15, 30, 45, 60, 90, 120, 150 and 180 min after the start of the OGTT. The ingestion of 6 g C. zeylanicum had no significant effect on glucose level, insulin response, GI or GII. Ingestion of C. zeylanicum does not affect postprandial plasma glucose or insulin levels in human subjects. The Federal Institute for Risk Assessment in Europe has suggested the replacement of C. cassia by C. zeylanicum or the use of aqueous extracts of C. cassia to lower coumarin exposure. However, the positive effects seen with C. cassia in subjects with poor glycaemic control would then be lost.

Key words: Glucose; Insulin; Ceylon cinnamon; Impaired glucose tolerance

The cinnamon tree is a member of the laurel family. Cinnamon is the inner bark of the cinnamon tree and is used as a spice. Ceylon cinnamon, with the botanical name Cinnamomum zeylanicum/verum is also known as ‘true cinnamon’. However, the related Cinnamomum cassia/aromaticus, Cinnamomum burmannii and Cinnamomum loreiri are also sold as cinnamon. According to an investigation of various herbs and medicinal plants, C. cassia and C. zeylanicum extracts are among the most effective in the regulation of blood glucose in vitro. A water-soluble polyphenol type-A polymer, isolated from C. burmannii, has been shown to enhance insulin action by stimulating the insulin receptor in vitro. The effects on insulin sensitivity of different species of cinnamon, C. cassia, C. burmannii, C. loreiri and C. zeylanicum, have been reported not to differ. However, in another experiment it was found that extract of C. cassia had a better effect on glucose and insulin levels in rats than an extract of C. zeylanicum. In a previous study on healthy subjects, we found that the ingestion of 6 g C. cassia powder reduced the postprandial glucose concentration and gastric emptying rate. We also found that an intake of 3 g C. cassia powder reduced postprandial insulin concentrations more noticeably than the ingestion of 1 g C. cassia powder, without affecting the postprandial glucose level or the gastric emptying rate in healthy subjects. However, ingestion of capsules containing the equivalent of 5 g C. cassia powder 12 h before, or in conjunction with, an oral glucose test in healthy men has been found to reduce the glucose response, while no difference was observed in the insulin response. The intake of capsules corresponding to 3 g C. cassia powder the night before an oral glucose tolerance test (OGTT) has been found to reduce the glucose response in healthy men, while no difference was observed in the insulin response. These effects were lost within 2 d of ceasing cinnamon intake after 2 weeks of daily C. cassia ingestion.

Abbreviations: AUC, area under the curve; GI, glycaemic index; GII, glycaemic insulinaemic index; IGT, impaired glucose tolerance; OGTT, oral glucose tolerance test.

* Corresponding author: J. Hlebowicz, fax +46 40 92 52 72, email joanna.hlebowicz@med.lu.se
Evidence of the positive effect of *C. cassia* supplementation on glycaemic control in people with type 2 diabetes is still inconclusive. Owing to the presence of a toxic component called coumarin, the Federal Institute for Risk Assessment (BfR) in Europe has recently warned against consuming large amounts of *C. cassia* powder. On the basis of experimental studies on hepatotoxicity in dogs, the BfR established that 0.1 mg coumarin/kg body weight per d could be ingested over a lifetime without posing a risk to health. In more recent studies on the use of coumarin as a medical product, nine out of 114 patients exhibited elevated levels of transaminases in serum. Analyses of cinnamon powder containing foods according to their effects on blood glucose. The GI was originally introduced by Jenkins et al. to classify carbohydrate-containing foods according to their effects on blood glucose. The GI is defined as the increase in the area under the curve (AUC) over 2 h, above the fasting blood glucose, after the ingestion of a test meal, divided by the response to a referent meal such as white bread or glucose. Impaired glucose tolerance (IGT) is associated with increased risk of developing type 2 diabetes. Studies suggest that IGT is associated with muscle insulin resistance and defective insulin secretion, resulting in less efficient disposal of the glucose load during the OGTT. Type 2 diabetes can be prevented by changes in the lifestyles of subjects with IGT. The present study was therefore designed to determine whether *C. zeylanicum* lowered postprandial glucose, insulin levels, GI and glycaemic insulinaemic index (GII) in subjects with IGT.

Experimental methods

A total of ten subjects with IGT (six male, four female; age 61 (SD 16) years (range 29–73 years); BMI 26.3 (SD 4.2) kg/m² (range 20.1–32.7 kg/m²) were included in the present crossover study. All subjects were recruited from the population in southern Sweden. Patients were selected for the present study on the basis of the diagnosis of IGT (fasting glucose <7.0 mmol/l, 2 h venous glucose ≥7.8 mmol/l and <11 mol/l). Glucose tolerance status and fasting plasma glucose levels were evaluated using the criteria established by the WHO. A standard 75 g OGTT was performed within 12 months before enrolment. Subjects who had thyroid disorders, or who had taken insulin or oral anti-diabetic drugs within 60 d before enrolment were excluded. Four subjects were smokers. The fasting glucose concentration of each subject was checked on the day of the examination to ensure that it was normal (<7.0 mmol/l).

Capsules containing either 560 mg lactose (Apotheke, Produktion & Laboratorier, Gothenburg, Sweden) or 400 mg *C. zeylanicum* and 100 mg lactose (Swampbutiken; Mediapoint AB, Västerås, Sweden) were prepared in advance by the Malmö University Hospital Pharmacy. Although both cinna-mon and placebo capsules appeared identical, it is possible that some of the participants could discern a difference between the two types of capsules. The subjects were examined between 07.30 and 10.30 hours after a 12 h fast. Smoking and snuff taking were prohibited 8 h before and during the test. The OGTT consisted of 75 g glucose to which 6.9 g lactose was added, and was ingested with fifteen capsules containing *C. zeylanicum*. The reference OGTT consisted of 75 g glucose, and was ingested with fifteen placebo capsules. The OGTT were served in random order at intervals of 1 week. Randomisation was performed using a table of random numbers.

Finger-prick capillary blood samples were taken to determine glucose levels, and venous blood for the determination of insulin concentrations, before and at 15, 30, 45, 60, 90, 120, 150 and 180 min after the start of the OGTT. Glucose concentrations were measured with the HemoCue Glucose system (HemoCue AB, Angelholm, Sweden), which converts blood glucose to plasma-equivalent glucose concentrations by multiplying by a constant factor of 1.11. The precision of the HemoCue Glucose system was better than 0.350 between 0 and 22.2 mmol/l. Insulin concentrations were measured using an immunoassay with an alkaline phosphatase conjugate (Access Ultrasensitive Insulin; Beckman-Coulter AB, Bromma, Sweden). The sensitivity of the insulin immunoassay was 0.05 μU/l, and the intra-assay CV was less than 10% in the interval 0.03–300 μU/l.

All subjects gave their written informed consent. The present study was approved by the Ethics Committee of Lund University, and was performed according to the Helsinki Declaration. The present study started on 11 May 2009 and ended on 11 September 2009. The trial registration no. is NCT01027585.

The incremental AUC were measured for plasma glucose and insulin in each subject using GraphPad Prism version 3.0 (GraphPad Software, San Diego, CA, USA). The AUC above the baseline was calculated. The GI and the GII were calculated from the 0–180 min AUC using each subject as their own reference. The GI and GII were calculated by expressing the increase in glucose level of each participant following the test meal as a percentage of the same participant’s response after the reference meal. All statistical calculations were performed using SPSS for Windows (version 14.0, 2005; SPSS, Inc., Chicago, IL, USA). Differences in the plasma glucose levels, insulin levels and glycaemic index were evaluated with Wilcoxon’s t test. Values of $P<0.05$ were considered significant. Differences in GI in ten subjects can be detected with 80% power at a level of $P<0.05$.  

---

**References**


Results

No significant differences were seen in glucose responses at different time periods, or in the incremental areas under the postprandial glucose curves, between the OGTT with and without *C. zeylanicum* (Fig. 1, Table 1). Neither were any significant differences seen in insulin responses at different time periods nor in the incremental areas under the postprandial insulin curves, between the OGTT with and without *C. zeylanicum* (Fig. 2, Table 1). No significant differences were seen in GI or GII between the meals with and without *C. zeylanicum* (Table 1).

Discussion

The aim of the present study was to elucidate the effect of *C. zeylanicum* on postprandial glucose and insulin levels in subjects with IGT. The present hypothesis was that an intake of *C. zeylanicum* would lower the postprandial glucose and insulin response. We were not able to verify this hypothesis. The present findings agree with those of Verspohl et al. (4) who found that the effect of extract of *C. cassia* on glucose and insulin in rats was superior to that of the extract of *C. zeylanicum*. However, the effects of *C. zeylanicum* on glucose and insulin levels have not been studied previously in human subjects. Regarding cinnamon, a distinction must be made between *C. zeylanicum* and *C. cassia*. *C. zeylanicum* contains hardly any coumarin in contrast to *C. cassia* (22). Administration of coumarin to diabetic rats indicates alterations in the metabolism of glucose, resulting in a reduction in plasma glucose levels (25, 24). It has also been suggested that coumarin may change the glucose metabolism in the rat liver, leading to reduced plasma glucose levels (25, 23). The effects of coumarin on glucose and insulin levels in human subjects have not been reported. However, it can be assumed that coumarin ingestion will also affect glucose metabolism in human subjects. In a total of forty-four *C. cassia* samples from various Asian countries, He et al. (13) identified levels of more than 1 g coumarin per kg dry cinnamon powder in ten samples; the maximum level measured was 12.2 g/kg. Miller et al. (14) reported coumarin levels from below the detection level to 0.19 g/kg in twelve *C. zeylanicum* samples, and between 0.7 and 12.2 kg/kg in twelve *C. cassia* samples. Unfortunately, the coumarin levels or structure in cinnamon powder were not measured in the present study or in our previous studies on the effects of cinnamon on glucose and plasma lipids in patients with type 2 or type 1 diabetes and in healthy human subjects. Studies on animals indicate that, depending on the structure of coumarins, there may be diverse toxicity (26). Coumarin is poorly soluble in water, and the BrF has therefore suggested the replacement of *C. cassia* by aqueous extracts of *C. cassia* to lower coumarin exposure.

In a study in Pakistan by Khan et al. (27), it was found that the ingestion of 1, 3 and 6 g *C. cassia* powder daily for 40 d lowered the levels of fasting glucose, TAG, LDL-cholesterol and total cholesterol in women and men with type 2 diabetes receiving oral glucose-lowering treatment. Mang et al. (28) found that treating women and men with type 2 diabetes with oral glucose-lowering medication or diet and/or physical activity and 3 g aqueous extract of *C. cassia* daily for 4 months resulted in a reduction in fasting plasma glucose levels, while no difference was observed in HbA1c, total cholesterol, LDL, HDL or TAG concentration. Vanschoonbeek et al. (29) found no improvement in HbA1c, fasting glucose or insulin concentration, TAG, LDL, HDL, total cholesterol or insulin resistance or sensitivity in overweight, postmenopausal women with type 2 diabetes, following either oral blood-glucose-lowering medication or controlled diets supplemented with 1.5 g *C. cassia* powder per d for 6 weeks. In a study performed in the USA, Blevins et al. (30) found no significant changes in fasting glucose, lipid, HbA1c or insulin levels in people

<table>
<thead>
<tr>
<th>Glucose AUC (mmol/l per min)</th>
<th>OGTT with placebo capsules</th>
<th>OGTT with <em>C. zeylanicum</em> capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–150 min</td>
<td>668.0</td>
<td>845.3</td>
</tr>
<tr>
<td>0–180 min</td>
<td>709.5</td>
<td>853.3</td>
</tr>
<tr>
<td>GI</td>
<td>189.7</td>
<td>236.5</td>
</tr>
<tr>
<td>Insulin AUC (µU/l per min)</td>
<td>OGTT with placebo capsules</td>
<td>OGTT with <em>C. zeylanicum</em> capsules</td>
</tr>
<tr>
<td>0–150 min</td>
<td>7512.7</td>
<td>1987.5</td>
</tr>
<tr>
<td>0–180 min</td>
<td>8823.6</td>
<td>2366.5</td>
</tr>
</tbody>
</table>

* Mean values were not significantly different between placebo and *C. zeylanicum* capsules. Values are means ± SEM.
with type 2 diabetes when 1 g *C. cassia* powder was consumed daily for 3 months. In the study in Pakistan by Khan, the fasting serum glucose concentrations of the subjects were between 11.4 and 16.7 mmol/l, which is approximately HbA1c values of 8.0—10.5%.[27] These results suggest that those with poorly controlled diabetes may benefit from cinnamon intake more than those receiving adequate treatment. Patients with type 1 diabetes treated with 1 g *C. cassia* powder per d for 3 months showed no difference in HbA1c, total daily insulin intake or number of hypoglycaemic episodes compared with the placebo group.[31] This may be explained by the fact that cinnamon decreases insulin resistance, which is not involved in the pathology of type 1 diabetes. However, a recent meta-analysis of the above-mentioned five randomised, placebo-controlled trials on patients with type 1 and type 2 diabetes did not show any significant changes in HbA1c, fasting glucose or lipid levels.[32] In women with polycystic ovary syndrome without diabetes, a dietary supplement of 333 mg *C. burmannii* extract, three times a day for 8 weeks, has been found to lower insulin resistance and fasting glucose levels.[33] A dietary supplement of 1.5 g *C. cassia* powder for 12 weeks in subjects with type 2 diabetes led to no significant changes in HbA1c, fasting glucose or lipid levels.[34]

**Conclusions**

The insulin-like biological activity of different species of cinnamon, *C. cassia*, *C. burmannii*, *C. loretirii* and *C. zeylanicum*, has been reported not to be different *in vitro* in rat epidymal fat cells,[33] and the BrF has suggested the replacement of *C. cassia* by *C. zeylanicum*, or the use of aqueous extracts of *C. cassia* to lower coumarin exposure for human subjects. However, the results of the present study show that the ingestion of *C. zeylanicum* does not affect postprandial plasma glucose or insulin levels in human subjects.

**Acknowledgements**

The present study was supported by Gifts and Foundations-Research Per Håkansson’s Foundation, Erhold Lundström’s Foundation for Medical Research and Diabetes Foundation Sydwest Skåne. J. H., J. N. and J. W. contributed to the design of the study; J. W. and K. B. were responsible for recruiting the subjects; J. W. carried out the practical aspects of the study. J. W., S. L. and J. H. conducted the statistical calculations; J. W. and J. H. wrote the first draft of the manuscript and J. N., S. L. and K. B. critically reviewed the manuscript. All authors read and approved the final manuscript. The authors declare that they have no competing interest.

**References**

Cinnamon, and impaired glucose tolerance


